• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

    11/14/24 7:00:55 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $REPL alert in real time by email
    SC 13G/A 1 d910286dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

    Replimune Group, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001

    (Title of Class of Securities)

    76029N106

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☐

    Rule 13d-1(c)

     

    ☒

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 76029N106    13G    Page 2 of 6 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Forbion Capital Fund III Coöperatief U.A.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     The Netherlands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     SOLE VOTING POWER

     

     0

       6.  

     SHARED VOTING POWER

     

     5,115,121*

       7.  

     SOLE DISPOSITIVE POWER

     

     0

       8.  

     SHARED DISPOSITIVE POWER

     

     5,115,121*

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,115,121*

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     7.5% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     OO

     

    *

    Includes 248,672 shares of common stock issuable upon exercise of warrants to purchase shares of common stock.

    1

    This percentage is calculated based upon (i) 68,321,396 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s quarterly report in Form 10-Q, filed with the Securities and Exchange Commission on August 8, 2024, plus (ii) 248,672 shares of common stock underlying warrants held by the Reporting Persons.


    CUSIP No. 76029N106    13G    Page 3 of 6 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Forbion III Management B.V.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     The Netherlands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     SOLE VOTING POWER

     

     0

       6.  

     SHARED VOTING POWER

     

     5,115,121*

       7.  

     SOLE DISPOSITIVE POWER

     

     0

       8.  

     SHARED DISPOSITIVE POWER

     

     5,115,121*

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,115,121

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     7.5% (2)

    12.  

     TYPE OF REPORTING PERSON

     

     OO

     

    *

    Includes 248,672 shares of common stock issuable upon exercise of warrants to purchase shares of common stock.

    2

    This percentage is calculated based upon (i) 68,321,396 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s quarterly report in Form 10-Q, filed with the Securities and Exchange Commission on August 8, 2024, plus (ii) 248,672 shares of common stock underlying warrants held by the Reporting Persons.


    Item 1(a).

    Name of Issuer:

    Replimune Group, Inc.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    500 Unicorn Park Drive, Suite 303, Woburn, MA 01801

     

    Item 2(a).

    Name of Person Filing:

    This Statement is being filed by Forbion Capital Fund III Coöperatief U.A. (“Forbion III COOP”), and Forbion III Management B.V. (“Forbion III”), the director of Forbion III COOP. Forbion III COOP and Forbion III are sometimes referred to collectively herein as the “Reporting Persons”.

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business and principal office of each of the Reporting Persons is c/o Forbion Capital Partners, Gooimeer 2-35, 1411 DC Naarden, The Netherlands.

     

    Item 2(c).

    Citizenship:

    Forbion Capital Fund III Coöperatief U.A. – The Netherlands

    Forbion III Management B.V. – The Netherlands

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, par value $0.001 per share

     

    Item 2(e).

    CUSIP Number:

    76029N106

     

    Item 3.

    Not applicable.

     

    Item 4.

    Ownership.

    Forbion III COOP is the beneficial owner of 5,115,121 shares of Common Stock, consisting of (i) 4,866,449 shares of common stock and (ii) 248,672 shares of common stock issuable upon exercise of warrants beneficially owned by the Reporting Persons. Forbion III, the director of Forbion III COOP, has voting and investment power over the shares held by Forbion III COOP.

     

      (a)

    Amount beneficially owned: 5,115,121

     

      (b)

    Percent of class: 7.5%

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote: 0

     

      (ii)

    Shared power to vote or to direct the vote: 5,115,121

     

      (iii)

    Sole power to dispose or to direct the disposition of: 0

     

      (iv)

    Shared power to dispose or to direct the disposition of: 5,115,121

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.


    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    The Reporting Persons are making this single, joint filing because they may be deemed to constitute a “group” within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Reporting Persons disclaim membership in a group and this report shall not be deemed an admission by any of the Reporting Persons that they are or may be members of a “group” for purposes of Rule 13d-5 or for any other purpose.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    Not applicable.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: November 14, 2024

     

    FORBION CAPITAL FUND III COÖPERATIEF U.A.
    By: Forbion III Management B.V.
    Its: Director

    /s/ G.J. Mulder

            

    /s/ V. van Houten

    Name: G.J. Mulder       V. van Houten
    Title: Directors      
    FORBION III MANAGEMENT B.V.

    /s/ G.J. Mulder

         

    /s/ V. van Houten

    Name: G.J. Mulder       V. van Houten
    Title: Directors      
    Get the next $REPL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $REPL

    DatePrice TargetRatingAnalyst
    8/28/2024$17.00Buy
    ROTH MKM
    4/17/2023$44.00Overweight
    Piper Sandler
    11/19/2021$52.00Overweight
    Piper Sandler
    10/15/2021$60.00Buy
    BTIG Research
    8/23/2021$55.00 → $49.00Outperform
    SVB Leerink
    8/9/2021$56.00 → $55.00Outperform
    SVB Leerink
    More analyst ratings

    $REPL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

      - RP1 plus nivolumab generated robust responses in both injected and non-injected lesions - - Deep/visceral injections, including into the liver and lung, resulted in numerically higher rates of response compared to superficial injections only and were generally well tolerated - WOBURN, Mass., June 01, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented two posters highlighting data updates for RP1 (vusolimogene oderparepvec) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago. "The new analyses we pres

      6/1/25 10:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune to Present at the 2025 Jefferies Global Healthcare Conference

      WOBURN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 4:20 PM ET. A simultaneous webcast will be available in the Investors section of Replimune's website at replimune.com. A replay will be available for 30 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering th

      5/29/25 8:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

      •  BLA priority review of RP1 plus nivolumab in advanced melanoma proceeding on schedule; manufacturing inspections and late cycle review meeting complete •  Full commercial infrastructure for launch in place ahead of July 22nd PDUFA date •  Conference call today at 8:00 AM ET WOBURN, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2025 and provided a business update. "As we near our PDUFA date, our commercial organization is now fully hired and ready to execute our fir

      5/22/25 7:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $REPL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Astley-Sparke Philip sold $260,169 worth of shares (32,279 units at $8.06), decreasing direct ownership by 2% to 1,405,071 units (SEC Form 4)

      4 - Replimune Group, Inc. (0001737953) (Issuer)

      5/22/25 9:47:07 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Xynos Konstantinos sold $64,093 worth of shares (7,952 units at $8.06), decreasing direct ownership by 5% to 146,933 units (SEC Form 4)

      4 - Replimune Group, Inc. (0001737953) (Issuer)

      5/22/25 9:46:09 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Accounting Officer Schwendenman Andrew sold $26,460 worth of shares (3,287 units at $8.05), decreasing direct ownership by 5% to 68,284 units (SEC Form 4)

      4 - Replimune Group, Inc. (0001737953) (Issuer)

      5/22/25 9:45:30 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $REPL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

      SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

      11/14/24 4:20:10 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

      SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

      11/14/24 1:22:38 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

      SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

      11/14/24 8:35:56 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $REPL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Replimune with a new price target

      ROTH MKM initiated coverage of Replimune with a rating of Buy and set a new price target of $17.00

      8/28/24 7:52:10 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler resumed coverage on Replimune with a new price target

      Piper Sandler resumed coverage of Replimune with a rating of Overweight and set a new price target of $44.00

      4/17/23 7:34:30 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Replimune Group with a new price target

      Piper Sandler initiated coverage of Replimune Group with a rating of Overweight and set a new price target of $52.00

      11/19/21 6:41:32 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $REPL
    SEC Filings

    See more
    • SEC Form S-3 filed by Replimune Group Inc.

      S-3 - Replimune Group, Inc. (0001737953) (Filer)

      5/22/25 9:34:00 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by Replimune Group Inc.

      S-3 - Replimune Group, Inc. (0001737953) (Filer)

      5/22/25 9:30:37 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Replimune Group Inc.

      S-8 - Replimune Group, Inc. (0001737953) (Filer)

      5/22/25 9:23:59 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $REPL
    Leadership Updates

    Live Leadership Updates

    See more
    • Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

      Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand's profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of cha

      5/8/25 5:00:00 AM ET
      $COYA
      $REPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

      Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization Preparations on track to submit RP1 biologics license application (BLA) in 2H 2024 WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced changes to its executive leadership team designed to support the Company's preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma. Sushil Patel, Ph.D., will succeed Philip

      3/26/24 7:30:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tessellate BIO Emerges from Stealth

      The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populationsLead program targets Alternative Lengthening of Telomeres (ALT) through the FANCM protein complexCompany backed by leading venture firms, BioGeneration Ventures (BGV) and ForbionWorld-class leadership team with proven experience as entrepreneurs and deep expertise in drug discovery and precision oncology AMSTERDAM and LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, has today emerged from stealth, with an initial €8m in s

      10/17/23 3:00:00 AM ET
      $NAMS
      $REPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $REPL
    Financials

    Live finance-specific insights

    See more
    • Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

      WOBURN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Thursday, May 22, 2025 at 8:00 a.m. ET to discuss its financial results for the fiscal fourth quarter and year end March 31, 2025. Additionally, the Company will host an Investor Day on Tuesday, June 24, 2025. Fiscal Fourth Quarter Earnings Replimune will release its fiscal year end earnings and host a conference call at 8:00 a.m. ET on May 22, 2025. Listeners can register for the webcast via this link. Analysts wishing to participate in the

      5/16/25 8:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

      Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 2024 Company to host conference call and webcast today at 8:00 a.m. ET WOBURN, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced the topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma. The results by independent central review show one-third of pat

      6/6/24 7:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

      RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary endpoints Positive data update for full 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma reinforces durable benefit; biologics license application (BLA) submission planned for 2H 2024 RP1 monotherapy data from ARTACUS clinical trial and new data from first 30 patients with anti-PD1 failed non-melanoma skin cancers in IGNYTE trial adds to growing body of evidence supporting the potential of RP1 in difficult to treat skin cancer s

      12/5/23 7:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care